Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central hyperthyroidism

M T McDermott1, E C Ridgway

  • 1Division of Endocrinology, University of Colorado Health Sciences Center, Denver, USA.

Endocrinology and Metabolism Clinics of North America
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Hormones and behavior·2013
Same author

Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al.

Frontiers in neuroendocrinology·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Andrology·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Hormone research in paediatrics·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

European journal of endocrinology·2013
Same author

Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al.

Endocrinology·2013
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Central hyperthyroidism, caused by TSH-producing pituitary tumors or PRTH, requires distinguishing from primary hyperthyroidism. Early diagnosis and appropriate treatment, such as surgery for TSHomas or medication for PRTH, are crucial for patient outcomes.

Area of Science:

  • Endocrinology
  • Pituitary Disorders
  • Thyroid Disorders

Background:

  • Central hyperthyroidism is a rare condition characterized by thyrotoxicosis due to excessive TSH from the pituitary.
  • The two main causes are TSH-producing pituitary tumors (TSHomas) and the syndrome of pituitary resistance to thyroid hormone (PRTH).
  • Distinguishing central from primary hyperthyroidism is critical, as primary forms have undetectable TSH levels, unlike central forms.

Purpose of the Study:

  • To outline the causes, diagnostic approaches, and treatment strategies for central hyperthyroidism.
  • To differentiate between TSHomas and PRTH based on specific clinical and biochemical markers.
  • To provide guidance on managing these rare pituitary and thyroid-related disorders.

Main Methods:

  • Differentiating TSHomas and PRTH using serum alpha-subunit levels, TSH response to TRH and thyroid hormone, and pituitary imaging.

Related Experiment Videos

  • Identifying TSHomas as benign adenomas from neoplastic thyrotropes.
  • Characterizing PRTH as a nonneoplastic disorder due to thyroid hormone receptor beta gene mutations.

    • Main Results:

    • TSHomas are typically benign pituitary adenomas.
    • PRTH involves pituitary resistance to thyroid hormone feedback, leading to thyrotoxicosis.
    • Diagnostic tools effectively differentiate between TSHomas and PRTH.

    Conclusions:

    • Central hyperthyroidism necessitates careful differentiation from primary hyperthyroidism.
    • TSHomas are best treated with surgery, potentially augmented by radiotherapy or octreotide.
    • PRTH management involves TSH suppression with medications or, if necessary, thyroid ablation.